Anzeige
Mehr »
Login
Donnerstag, 09.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40X9W | ISIN: CA07135M2031 | Ticker-Symbol: 5YW
Frankfurt
08.01.25
18:46 Uhr
0,150 Euro
+0,029
+23,97 %
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
BATTERY X METALS INC Chart 1 Jahr
5-Tage-Chart
BATTERY X METALS INC 5-Tage-Chart
ACCESSWIRE
217 Leser
Artikel bewerten:
(1)

Battery X Metals Announces Repricing of Warrants

Finanznachrichten News

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESSWIRE / January 7, 2025 / Battery X Metals Inc. (CSE:BATX)(OTCQB:BATXD)(FSE:R0W, WKN:A3EMJB)("Battery X Metals" or the "Company") announces the repricing of an aggregate of 3,554,993 common share purchase warrants (the "Repriced Warrants") to a revised exercise price of $0.25 per Repriced Warrant, effective immediately (the "Warrant Repricing"). Under the policies of the Canadian Securities Exchange (the "CSE"), the Warrant Repricing is subject to the unanimous consent of the registered holders of the outstanding Repriced Warrants.

Following the Company's 3.3:1 share consolidation effective December 10, 2024 (the "Consolidation"), of the 3,554,993 Repriced Warrants:

  • 1,294,392 had an original exercise price of $0.66 ($0.20 pre-Consolidation) and an expiry date of January 24, 2026;

  • 355,151 had an original exercise price of $0.66 ($0.20 pre-Consolidation) and an expiry date of February 9, 2026;

  • 1,496,360 had an original exercise price of $0.33 ($0.10 pre-Consolidation) and an expiry date of July 29, 2026; and

  • 409,090 had an original exercise price of $0.33 ($0.10 pre-Consolidation) and an expiry date of September 3, 2026.

As the Warrant Repricing will result in an exercise price lower than the market price of the Company's common shares on the date the warrants were issued, CSE policies require that, if following the Warrant Repricing, for any ten consecutive trading days the closing price of the Company's common shares on the CSE exceeds the amended exercise price by 25%, the term of the Repriced Warrants must be amended to 30 days. The amended expiry date will be announced by the Company by press release and the 30-day period will commence seven days from the end of the ten consecutive trading day period referred to above.

About Battery X Metals Inc.

Battery X Metals (CSE:BATX) (OTCQB:BATXD) (FSE:R0W, WKN:A3EMJB) is committed to advancing the global clean energy transition through the development of proprietary technologies and domestic battery and critical metal resource exploration. The Company focuses on extending the lifespan of electric vehicle (EV) batteries, through its portfolio company, LIBRT1, recovering battery grade metals from end-of-life lithium-ion batteries, and the acquisition and exploration of battery and critical metals resources. For more information, visit batteryxmetals.com.

149% owned Portfolio Company

On Behalf of the Board of Directors

Massimo Bellini Bressi, Director

For further information, please contact:

Massimo Bellini Bressi

Chief Executive Officer

Email: mbellini@batteryxmetals.com

Tel: (604) 741-0444

Disclaimer for Forward-Looking Information

This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements in this release include, but are not limited to, statements regarding the Company's objectives, business strategies, and future plans, including completion of the Warrant Repricing and compliance with securities laws. These forward-looking statements are based on management's current expectations and assumptions, which are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Risks include, but are not limited to, changes in market conditions, regulatory risks, the inability to achieve regulatory compliance or approvals, reliance on key personnel, that the holders of the Repriced Warrants may not consent to the Warrant Repricing and the risk factors set forth in the Company's filings on SEDAR+. Forward-looking statements are made as of the date of this release, and Battery X Metals disclaims any obligation to update or revise them to reflect new events or circumstances, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

SOURCE: Battery X Metals



View the original press release on accesswire.com

© 2025 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.